Clinical Trial Update: A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases [EARLY_Phase 1]

View source ↗

Summary

A Phase 0/1 study of GSK5764227, a B7-H3-targeted antibody-drug conjugate, in patients with recurrent grade 4 glioma (including glioblastoma) and brain metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Glioblastoma

Drugs mentioned

• GSK5764227

Snippet

Sponsor: Nader Sanai | Conditions: Glioblastoma (GBM), Brain Metastasases | EARLY_Phase 1 | Status: RECRUITING